rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    APRE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
      Nov 5Yahoo FinanceAPRE
      Zentalis Validates a Multibillion-Dollar Cancer Market as Aprea Therapeutics Emerges as a Next-Generation Contender
      Oct 22BarchartAPREZNTL
      Zentalis Validates a Multibillion-Dollar Cancer Market as Aprea Therapeutics Emerges as a Next-Generation Contender
      Oct 21BarchartAPREZNTL
      Aprea at Pre-ESMO Virtual Panel Conference: wEE1 bet leans on safety
      Oct 20Investing.comAPRE
      Aprea Therapeutics to Present at October Conferences

      Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15)DOYLESTOWN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad PhD, President and CEO, will participate in the 2026 Maxim Growth Summit,

      Oct 5Yahoo FinanceAPRE
      Aprea Therapeutics to present WEE1 inhibitor trial data in November
      Sep 22Investing.comAPRE
      Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
      Sep 22Yahoo FinanceAPRE
      Aprea Therapeutics at H.C. Wainwright conference: early data lifts outlook
      Sep 14Investing.comAPRE
      Aprea Therapeutics reports patent portfolio of 58 patents
      Aug 28Investing.comAPRE
      Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

      Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents

      Aug 28BarchartAPRE
      Aprea Therapeutics records second consecutive surge, jumping another 22% (APRE:NASDAQ)
      Aug 25Seeking AlphaAPRE

      This is the newest page. Registered accounts read further back.